Immunic to Participate in Investor Conferences in July
Biotechnology company Immunic announced its participation in several investor conferences throughout July. The company will present information on its research and development efforts in neurologic diseases.
NEW YORK – In July 2026, biotechnology company Immunic, Inc. will participate in multiple investor conferences to engage with investors and present updates on its progress in developing therapies for neurologic diseases.
Company executives, including CEO Erik Lundgren, are scheduled to attend the Leerink Partners Therapeutics Forum in Boston from July 14-15. Following this, they will participate in the B. Riley Securities Mind, Muscle & Vision Summit on July 16, where Lundgren will deliver a fireside chat. Immunic will also be present at the LifeSci Capital SF Biotech Forum in San Francisco on July 23.
Immunic focuses on developing novel oral therapies for neurologic conditions. The company's lead program, vidofludimus calcium (IMU-838), is currently undergoing Phase 3 clinical trials for relapsing multiple sclerosis, with top-line data anticipated by the end of 2026.
The company is also advancing other pipeline candidates, including IMU-856 and IMU-381, aimed at addressing neurodegenerative, chronic inflammatory, and autoimmune diseases. These conferences provide a platform for Immunic to discuss its development pipeline and future outlook with interested investors.